1. 2022

2. Economic evaluation of Tislelizumab Versus Chemotherapy as Second Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

   Shi, F., He, Z., Su, H., Wang, L. & Han, S., 16 Nov 2022, In: Frontiers in Pharmacology. 13

   Research output: Contribution to journal › Article › peer-review

3. Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study

   Shi, F., He, Z., Wang, L., Su, H. & Han, S., 18 Oct 2022, In: Frontiers in Pharmacology. 13

   Research output: Contribution to journal › Article › peer-review